Cargando…

Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma

BACKGROUND: The purpose of this study was to develop prognostic nomograms from a cohort of patients with triple-negative breast cancer (TNBC) with histology of infiltrating duct carcinoma (IDC) by correlating their clinical and pathological parameters with the rates of disease-free survival (DFS) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Na, Ma, Ming-Wei, Gao, Xian-Shu, Liu, Jian-Ting, Gu, Xiao-Bin, Zhang, Min, Zhao, Bo, Wang, Yu, Wang, Xian-Ling, Jia, Hai-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723543/
https://www.ncbi.nlm.nih.gov/pubmed/33313192
http://dx.doi.org/10.21037/atm-20-413
_version_ 1783620360833335296
author Jing, Na
Ma, Ming-Wei
Gao, Xian-Shu
Liu, Jian-Ting
Gu, Xiao-Bin
Zhang, Min
Zhao, Bo
Wang, Yu
Wang, Xian-Ling
Jia, Hai-Xia
author_facet Jing, Na
Ma, Ming-Wei
Gao, Xian-Shu
Liu, Jian-Ting
Gu, Xiao-Bin
Zhang, Min
Zhao, Bo
Wang, Yu
Wang, Xian-Ling
Jia, Hai-Xia
author_sort Jing, Na
collection PubMed
description BACKGROUND: The purpose of this study was to develop prognostic nomograms from a cohort of patients with triple-negative breast cancer (TNBC) with histology of infiltrating duct carcinoma (IDC) by correlating their clinical and pathological parameters with the rates of disease-free survival (DFS) and overall survival (OS). METHODS: We retrospectively analyzed TNBC patients with histology of IDC at our institution between 2009 and 2012. Age, family history, menopausal status, surgery type, T stage, N stage, histological grade, vascular invasion, perineural invasion, cytokeratin 5/6 status, Ki-67 expression, and epithelial cadherin (E-cadherin) status were analyzed. Predictors were used in multivariable logistic regression analysis to develop a nomogram to predict DFS and OS rates. The nomograms were then subjected to internal validation, with external validation of the nomogram for predicting OS using separate cohorts of TNBC patients known from the Cancer Genome Atlas (TCGA) database. Using the concordance index (C-index) with calibration curves, the predictive accuracy and discriminative ability were calculated. RESULTS: A total of 242 eligible TNBC patients were included for analysis. The median follow-up time was 70.73 months. Of the patients, 32.6%, 42.6%, and 24.8% had stage I, II, and III disease, respectively. The 3- and 5-year survival rates were 81.0% and 76.5% for DFS, and 86.5% and 81.1%, for OS, respectively. Age, T stage, N stage, and E-cadherin status were found to be risk factors. The nomograms based on those risk factors accurately predicted the 3- and 5-year survival rates. The C-index was 0.798 and 0.821 for DFS and OS, respectively. Besides, the nomogram for OS showed relatively reliable performance in stratifying different risk groups of patients in training and validation cohorts identified from the TCGA database. The C-index reached 0.843. DFS validation was not completed, as there was insufficient data. CONCLUSIONS: Using clinicopathological information, we produced a prognostic nomogram that accurately predicts the 3- and 5-year DFS and OS for patients with TNBC with histology of IDC. More external confirmation is required.
format Online
Article
Text
id pubmed-7723543
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77235432020-12-10 Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma Jing, Na Ma, Ming-Wei Gao, Xian-Shu Liu, Jian-Ting Gu, Xiao-Bin Zhang, Min Zhao, Bo Wang, Yu Wang, Xian-Ling Jia, Hai-Xia Ann Transl Med Original Article BACKGROUND: The purpose of this study was to develop prognostic nomograms from a cohort of patients with triple-negative breast cancer (TNBC) with histology of infiltrating duct carcinoma (IDC) by correlating their clinical and pathological parameters with the rates of disease-free survival (DFS) and overall survival (OS). METHODS: We retrospectively analyzed TNBC patients with histology of IDC at our institution between 2009 and 2012. Age, family history, menopausal status, surgery type, T stage, N stage, histological grade, vascular invasion, perineural invasion, cytokeratin 5/6 status, Ki-67 expression, and epithelial cadherin (E-cadherin) status were analyzed. Predictors were used in multivariable logistic regression analysis to develop a nomogram to predict DFS and OS rates. The nomograms were then subjected to internal validation, with external validation of the nomogram for predicting OS using separate cohorts of TNBC patients known from the Cancer Genome Atlas (TCGA) database. Using the concordance index (C-index) with calibration curves, the predictive accuracy and discriminative ability were calculated. RESULTS: A total of 242 eligible TNBC patients were included for analysis. The median follow-up time was 70.73 months. Of the patients, 32.6%, 42.6%, and 24.8% had stage I, II, and III disease, respectively. The 3- and 5-year survival rates were 81.0% and 76.5% for DFS, and 86.5% and 81.1%, for OS, respectively. Age, T stage, N stage, and E-cadherin status were found to be risk factors. The nomograms based on those risk factors accurately predicted the 3- and 5-year survival rates. The C-index was 0.798 and 0.821 for DFS and OS, respectively. Besides, the nomogram for OS showed relatively reliable performance in stratifying different risk groups of patients in training and validation cohorts identified from the TCGA database. The C-index reached 0.843. DFS validation was not completed, as there was insufficient data. CONCLUSIONS: Using clinicopathological information, we produced a prognostic nomogram that accurately predicts the 3- and 5-year DFS and OS for patients with TNBC with histology of IDC. More external confirmation is required. AME Publishing Company 2020-11 /pmc/articles/PMC7723543/ /pubmed/33313192 http://dx.doi.org/10.21037/atm-20-413 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Jing, Na
Ma, Ming-Wei
Gao, Xian-Shu
Liu, Jian-Ting
Gu, Xiao-Bin
Zhang, Min
Zhao, Bo
Wang, Yu
Wang, Xian-Ling
Jia, Hai-Xia
Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title_full Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title_fullStr Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title_full_unstemmed Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title_short Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
title_sort development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723543/
https://www.ncbi.nlm.nih.gov/pubmed/33313192
http://dx.doi.org/10.21037/atm-20-413
work_keys_str_mv AT jingna developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT mamingwei developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT gaoxianshu developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT liujianting developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT guxiaobin developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT zhangmin developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT zhaobo developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT wangyu developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT wangxianling developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma
AT jiahaixia developmentandvalidationofaprognosticnomogramforpatientswithtriplenegativebreastcancerwithhistologyofinfiltratingductcarcinoma